In This Article:
PainReform ( (PRFX) ) has provided an update.
Don't Miss Our New Year's Offers:
-
Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
-
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
PainReform announced that its Phase 3 clinical trial for PRF-110 did not meet its primary endpoint of providing effective postoperative pain relief over 72 hours, as data from the final 24-hour period could not be clarified. Despite this setback, the company is engaging in further R&D efforts to refine the drug’s pharmaco-kinetics and pharmaco-dynamics to potentially support future trials, reflecting their commitment to enhancing pain relief solutions for surgical patients.
More about PainReform
PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics. Their lead product, PRF-110, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. It is designed to provide extended postoperative analgesia directly at the surgical site, reducing the need for repeated doses and minimizing opiate use.
YTD Price Performance: -92.58%
Average Trading Volume: 3,218,022
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.89M
Learn more about PRFX stock on TipRanks’ Stock Analysis page.